bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-22. Numbers and descriptions here follow the published literature rather than marketing material.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
3 May Drug company Eli Lilly reports that donanemab can slow the pace of Alzheimer's disease by 35%, following a Phase 3 study in human patients. Astronomers using the Gemini South telescope report the first direct evidence of an exoplanet being swallowed by an ancient Sun-like star, a fate that likely awaits the Earth in five billion years. 4 May – Westinghouse Electric's nuclear division announces the AP300, a miniature version of its signature AP1000 nuclear reactor. 5 May – The World Health Organization announces that COVID-19 is no longer considered a global health emergency. 8 May The first infrared image of an asteroid belt outside the Solar System is captured by the James Webb Space Telescope. Three distinct rings of debris are shown to exist around Fomalhaut, a young star 25 light years away. AI successfully identifies people at the highest risk for pancreatic cancer up to three years before diagnosis, using solely the patients' medical records. 10 May A rough draft of the human "pan-genome" is presented, consisting of 47 genomes from a cohort of genetically diverse individuals. This aims to improve medical research by building on the earlier Human Genome Project. Scientists demonstrate with experimental evolution how macroscopic multicellularity could have emerged on Earth. 11 May – The discovery of 62 new moons of Saturn is reported, taking its total confirmed number to 145 and overtaking Jupiter. 15 May The National Institutes of Health begins a Phase 1 trial of an mRNA-based universal influenza vaccine, enrolling 50 volunteers.
== External links == Kavkaz-2008 leaflet ("Soldier, know your probable enemy"), The Guns of August 2008: Russia's War in Georgia, p. xi - xii Anna Nemtsova, Q&A: Georgia's Mikheil Saakashvili on Russia Fight, Newsweek, 11 August 2008 William Rees-Mogg, Georgia: another Sarajevo moment avoided, The Times, 11 August 2008 Illarionov: Russia Lost the Georgian War, The Other Russia, 13 August 2008 (in Russian) "We Will never surrender", Der Spiegel, 18 August 2008 (in Russian) Vadim Rechakolv's comment on the movement of Russian tank column through the Roki Tunnel on 7 August Denis Macshane, Denis MacShane Explores the Myths About Russia, Newsweek, 5 September 2008 Ministry of Foreign Affairs of Georgia, Media and telephone intercepts confirm Russia started the war, 20 September 2008 (in Russian) André Glucksmann, Putin's doctrine, 22 October 2008 The Government of Georgia, Factual Evidence Contradicts War Claims in Recent Media Stories;, 18 November 2008 Bear on the Prowl? The Return of Russia as a Great Power Archived 17 March 2024 at the Wayback Machine; Australian Institute of International Affairs, November 2008 Julia Latynina - Articles on August war (Translations) Report by the Government of Georgia on the aggression by the Russian Federation against Georgia, 7 August 2009. PDF file. (in Russian) Grani TV, Andrei Nekrasov, Movie director, Garry Kasparov about "Russian Lessons", 14 September 2009 Caucasus Analytical Digest No.
Platelets contain dense granules, lambda granules, and alpha granules. Activated platelets secrete the contents of these granules through their canalicular systems to the exterior. Bound and activated platelets degranulate to release platelet chemotactic agents to attract more platelets to the site of endothelial injury. Granule characteristics:
== History == The StAR protein was first identified, characterized and named by Douglas Stocco at Texas Tech University Health Sciences Center in 1994. The role of this protein in lipoid CAH was confirmed the following year in collaboration with Walter Miller at the University of California, San Francisco. All of this work follows the initial observations of the appearance of this protein and its phosphorylated form coincident with factors that caused steroid production by Nanette Orme-Johnson while at Tufts University.
Sources: en.wikipedia.org
Whose power is to be balanced? Today, no nation or group challenges American power … In fact, should the balance of power operate in its classical form, it would trigger countermoves by states seeking to pose a counterweight to America's expressed ambitions. According to Leffler's exegesis, Bush has invoked a balance of power vocabulary in purpose to integrate the tradition with the hegemonic dilemma. British Orwell Prize-winning policy analyst, Anatol Lieven, comments: In this conception, however, a phrase "was a form of Orwellian doublespeak. The clear intention actually was to be so strong that other countries had no choice but to rally to the side of the United States, concentrating all real power and freedom of action in the hands of America." The surprising rehabilitation of the balance-of-power term in the 2002 NSS "can be accounted for in terms of mythopoetic function that the terminology serves in the document." It keeps alive the traditional concept in a new unipolar world.
Self-amplifying mRNA (saRNA) vaccines replicate their mRNA after transfection. Self-amplifying mRNA has two open reading frames. The first frame, like conventional mRNA, codes for the antigen of interest. The second frame codes for an RNA-dependent RNA polymerase (and its helper proteins) which replicates the mRNA construct in the cell. This allows smaller vaccine doses. The mechanisms and consequently the evaluation of self-amplifying mRNA may be different, as self-amplifying mRNA is a much bigger molecule. SaRNA vaccines being researched include a malaria vaccine. The first saRNA Covid vaccine authorised was Gemcovac, in India in June 2022. The second was ARCT-154, developed by Arcturus Therapeutics. A version manufactured by Meiji Seika Pharma was authorised in Japan in November 2023. GSK began a phase 1 trial of an saRNA COVID-19 vaccine in 2021. Gritstone bio started also started a phase 1 trial of an saRNA COVID-19 vaccine in 2021, used as a booster vaccine, with interim results published in 2023. The vaccine is designed to target both the spike protein of the SARS‑CoV‑2 virus, and viral proteins that may be less prone to genetic variation, to provide greater protection against SARS‑CoV‑2 variants. saRNA vaccines must use uridine, which is required for reproduction to occur.
=== Hemolytic effect === Guanacastepene A also exhibits a significant toxic side effect in that it possesses pronounced hemolytic activity, which leads to the lysis of erythrocytes (human red blood cells). The strongest hemolytic effect was observed in laboratory tests at concentrations between 8 and 32 µg/ml. However, this effect diminishes at very high concentrations (above 64 µg/ml) as well as at very low concentrations (below 8 µg/ml). The mechanism of cell membrane damage is not selective enough for bacteria; eukaryotic cell membranes are also affected by the damaging effect of Guanacastepene A.
Sources: en.wikipedia.org
== Differentiation from internet peptides == Peptide therapeutics are not to be confused with the mid 2020s peptide trend; peptides (some off-label and some illegal) with unconfirmed safety and efficacy have recently become popular through social media influencers. Peptides are fragile, and thus are not generally absorbed by skin. However, emerging techniques such as nano-emulsion allows for some uptake of peptides through the skin. There is insufficient evidence for the safety or efficacy of most injected peptides in humans. Many peptides have only been tested on lab grown cells, and have not yet progressed to testing in animal models or humans. One off-label use of peptides is circumventing bans on the prescription of human growth hormone (HGH) by using tesamorelin or Sermorelin; that approach however carries the same downsides as regular HGH prescription, including increased risk of cancer, diabetes, and abnormal bone growth. Another influencer promoted peptide is TB-500, which has not undergone human testing and which at high levels is associated with tumor development. The United States, under the direction of Robert F. Kennedy Jr., has sought to deregulate various trendy peptides. Many Americans have gained access to "research grade" peptides sourced from China, which are not intended for widespread use. In July 2026, an advisory panel to the FDA (with 14 members, six of whom were peptide sellers), advised the FDA to deregulate six peptides, including BPC-157.
Best opium 1/2 dr., dissolve it in about 2 tbsp [30 mL] of boiling water; then add benzoic acid 1/2 dr.; oil of anise 1/2 a fluid dr.; clarified honey 1 oz.; camphor gum 1 scruple; alcohol, 76 percent, 11 fluid ozs.; distilled water 4-1/2 fluid ozs.; macerate, (keep warm,) for two weeks. Dose – For children, 5 to 20 drops, adults, 1 to 2 tea-spoons. A dram (dr.) is about 1.8 grams, a modern teaspoon is 5 mL, and a scruple is 1⁄4 teaspoon.
In August 2016, Biden visited Serbia, where he met with the Serbian Prime Minister Aleksandar Vučić and expressed condolences for civilian victims of the bombing campaign during the Kosovo War. Biden never cast a tie-breaking vote in the Senate, making him the longest-serving vice president with this distinction. During his second term, Biden was often said to be preparing for a bid for the 2016 Democratic presidential nomination. With his family, friends, and donors encouraging him in mid-2015 to enter the race, and with Hillary Clinton's favorability ratings in decline at that time, Biden was reported to be seriously considering the prospect and a "Draft Biden 2016" Political action committee (PAC) was established. During 2015, Biden was uncertain about running, particularly due to the recent death of his son Beau, before announcing his decision not to run that October.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.